Doxepin (Silenor): What It Is, How It Works, and How It Compares to Other Sleep Aids

What Is Doxepin (Silenor) and Why Does the Dose Matter So Much?

Doxepin is a tricyclic compound that has been prescribed in doses of 75 to 300 mg for depression since the 1960s. The branded formulation Silenor uses a dose 10-to-100 times lower: 3 mg or 6 mg. At those micro-doses, the drug's antidepressant, anticholinergic, and adrenergic effects become negligible, while its very high affinity for histamine H1 receptors remains fully active.

Histamine is a wake-promoting neurotransmitter released by neurons in the tuberomammillary nucleus of the hypothalamus. By selectively blocking H1 receptors at the end of the sleep period, doxepin 3 to 6 mg reduces early-morning awakening without suppressing sleep architecture the way benzodiazepines and z-drugs do. The FDA approved Silenor in May 2010 specifically for sleep-maintenance insomnia based on this targeted pharmacology.

That mechanistic specificity is relevant clinically. A 2010 Phase 3 randomized controlled trial (N=221) published data showing doxepin 6 mg significantly reduced wake time after sleep onset (WASO) compared to placebo across a 35-night study period (P<0.001), with no evidence of rebound insomnia on nights 36, 37 after abrupt discontinuation. [1] A companion trial (N=254) in adults 65 years and older showed doxepin 3 mg and 6 mg both reduced WASO and increased total sleep time versus placebo (P<0.01 for all comparisons), important evidence because older adults are especially vulnerable to next-day sedation from higher-dose hypnotics. [2]

The FDA label notes: "The recommended dose of SILENOR is 6 mg once daily for adults and 3 mg once daily for elderly patients. The 3 mg dose may be increased to 6 mg if clinically indicated." [3] Both doses are to be taken within 30 minutes of bedtime, and patients should have 7 to 8 hours available for sleep before planned awakening.

How Doxepin's Sleep Mechanism Differs from Z-Drugs and Benzodiazepines

Sleep drugs do not all work the same way. Zolpidem (Ambien), eszopiclone (Lunesta), and zaleplon (Sonata) all act on GABA-A receptors, the same receptor family targeted by benzodiazepines. Positive allosteric modulation of GABA-A receptors produces sedation rapidly but also suppresses slow-wave sleep, carries a risk of rebound insomnia after discontinuation, and can produce tolerance over weeks to months.

Doxepin at 3 to 6 mg works through a completely separate pathway: selective histamine H1 antagonism. This distinction has several practical consequences.

No DEA scheduling. Because doxepin lacks the abuse potential of GABA-modulating drugs, it carries no controlled-substance designation. Zolpidem, eszopiclone, and zaleplon are all Schedule IV. Patients with a history of substance use disorder who need a sleep-maintenance agent may be better served by doxepin than by z-drugs, though clinical judgment governs every such decision.

Sleep architecture is largely preserved. Polysomnographic data from the Phase 3 adult trial showed no statistically significant suppression of REM sleep or slow-wave sleep with doxepin 6 mg. [1] Zolpidem 10 mg, by comparison, has been shown in polysomnography studies to reduce slow-wave sleep time. [4]

Rebound insomnia appears absent. The adult Phase 3 trial included a two-night discontinuation phase; doxepin-treated subjects showed no worsening of WASO relative to placebo on nights 36 and 37. [1] That same clean discontinuation profile has not been reliably demonstrated with nightly zolpidem or eszopiclone use.

Onset is slower. Zolpidem and zaleplon reach peak plasma concentration in roughly 1 to 2 hours and produce rapid sleep-onset effects. Doxepin at these doses peaks around 3.5 hours after oral administration, making it more suitable for sleep-maintenance (staying asleep) than sleep-onset (falling asleep) problems.

Doxepin Dosing, Administration, and FDA Label Requirements

The approved doses are 3 mg and 6 mg. Both are oral tablets taken within 30 minutes of bedtime. The FDA label carries three critical administration instructions that clinicians and patients alike must follow: [3]

1. Take only when 7 to 8 hours of sleep remain before the expected wake time.
2. Do not take with or immediately after a high-fat meal; food can delay absorption and peak concentration.
3. Do not drive or operate heavy machinery the morning after use until patients know how the drug affects them.

For adults without special considerations, the usual starting dose is 6 mg. For patients 65 years and older, the starting dose is 3 mg, with optional titration to 6 mg. There is no approved dose above 6 mg for the sleep indication. Using higher doses (the antidepressant range) for insomnia is off-label and dramatically increases anticholinergic and cardiovascular adverse effects.

Generic doxepin tablets at these low doses are commercially available at most pharmacies. Because the branded Silenor formulation is simply doxepin in a low-dose tablet, the generic is therapeutically equivalent and substantially cheaper for most patients without insurance coverage for brand-name medications.

Side Effects, Contraindications, and Drug Interactions

At 3 to 6 mg, doxepin's side-effect profile is narrower than at antidepressant doses, but not trivial.

Common adverse effects (from Phase 3 pooled data): somnolence or sedation (reported by roughly 6% of doxepin 6 mg subjects vs. 3% placebo), nausea (2% vs. 1%), and upper respiratory tract infection (5% vs. 4%). [1][2] Anticholinergic effects like dry mouth and constipation, which are pronounced at antidepressant doses, are uncommon at 3 to 6 mg but can still occur, particularly in older adults who are already on multiple anticholinergic medications.

Next-day sedation and driving. A dedicated driving simulation study found no significant impairment the morning after doxepin 6 mg in adults, but the FDA still requires a cautionary label because individual pharmacokinetic variability is real.

Absolute contraindications: untreated narrow-angle glaucoma, significant urinary retention, and concomitant use of monoamine oxidase inhibitors (MAOIs) or use within 14 days of discontinuing an MAOI. [3]

Drug interactions: Doxepin is metabolized by CYP2D6 and CYP1A2. Inhibitors of CYP2D6 (such as fluoxetine, paroxetine, or bupropion) can raise doxepin plasma levels substantially. Central nervous system depressants including alcohol, benzodiazepines, opioids, and antihistamines produce additive sedation. Cimetidine (a CYP2D6 and CYP2C19 inhibitor) has been shown to increase doxepin exposure by approximately 2-fold; the label recommends avoiding cimetidine or limiting doxepin to 3 mg if coadministration is unavoidable. [3]

Cardiac considerations. At antidepressant doses, doxepin causes QTc prolongation and orthostatic hypotension. These effects are not reliably seen at 3 to 6 mg in healthy subjects, but the 2012 FDA Drug Safety Communication advised caution in patients with pre-existing cardiac disease. Clinicians should factor in baseline QTc when prescribing for any patient with cardiovascular risk factors. [5]

Doxepin vs. Melatonin: Two Very Different Tools

Melatonin and doxepin are frequently compared because both are used for sleep and neither is a controlled substance, but they address different problems through entirely different mechanisms.

Melatonin is a hormone secreted by the pineal gland that signals circadian timing. Exogenous melatonin (0.5 to 5 mg) shortens sleep-onset latency by roughly 7 minutes (weighted mean difference) in meta-analytic data across 19 trials, with minimal effect on WASO or total sleep time in primary insomnia. [6] It works best for circadian-phase disorders: jet lag, delayed sleep phase disorder, and shift-work disorder.

Doxepin 3 to 6 mg, in contrast, targets histaminergic arousal at the tail end of the sleep period. Its primary documented benefit is reducing WASO and increasing total sleep time in patients who fall asleep adequately but wake too early or too frequently. Melatonin has little efficacy for that presentation.

A practical clinical heuristic: if a patient says "I can't fall asleep," melatonin (or a melatonin receptor agonist like ramelteon) addresses circadian timing and may help. If the patient says "I fall asleep fine but wake at 3 or 4 a.m. and can't get back to sleep," doxepin 3 to 6 mg is supported by Phase 3 data for exactly that complaint.

Neither melatonin nor doxepin requires DEA scheduling. The difference is that melatonin is sold over the counter as a dietary supplement and is not FDA-regulated for efficacy, while doxepin is a prescription drug with two controlled Phase 3 trials supporting its indication.

Doxepin vs. Zolpidem (Ambien): Comparing the Evidence

Zolpidem immediate-release (Ambien) 5 to 10 mg and doxepin 3 to 6 mg are both FDA-approved for insomnia, but their evidence bases and risk profiles differ considerably.

Zolpidem's GABA-A mechanism produces rapid sleep onset. A 2012 FDA Safety Communication downgraded the recommended doses for zolpidem IR to 5 mg (women) and 5 to 10 mg (men) due to next-morning blood zolpidem levels impairing driving performance; a subsequent update in 2013 extended this warning to extended-release formulations. [5] The American Academy of Sleep Medicine (AASM) 2017 Clinical Practice Guideline for chronic insomnia "suggests" zolpidem for sleep-onset and sleep-maintenance insomnia but notes the evidence is moderate quality. [7]

The same AASM guideline also includes a "suggests" recommendation for doxepin specifically for sleep-maintenance insomnia. [7] The two drugs have not been compared in a head-to-head randomized trial, so direct efficacy comparisons must be interpreted cautiously.

Key differentiators in practice:

• Schedule: Zolpidem is Schedule IV; doxepin is unscheduled.
• Rebound: Zolpidem carries a clear rebound insomnia risk on discontinuation; doxepin Phase 3 data show no rebound signal.
• Sleep architecture: Zolpidem reduces slow-wave sleep; doxepin does not appear to do so at approved doses.
• Older adults: The Beers Criteria (American Geriatrics Society) flags all z-drugs including zolpidem as potentially inappropriate in adults 65 and older due to falls, fractures, and cognitive effects. [8] Doxepin 3 mg has a specific FDA approval and Phase 3 data in that age group. [2]

Doxepin vs. Eszopiclone (Lunesta) and Zaleplon (Sonata)

Eszopiclone (Lunesta) is the only z-drug with an FDA approval that lacks a time-limit restriction, meaning it may be used beyond 35 days without specific label caveats. A 6-month randomized trial (N=788) showed eszopiclone 3 mg maintained efficacy without tolerance across the study period. [9] Like zolpidem, eszopiclone is Schedule IV, carries a rebound insomnia risk, and is flagged by the Beers Criteria in older adults. A distinctive side effect is a persistent metallic or bitter taste reported by roughly 34% of patients at the 3 mg dose. [9]

Zaleplon (Sonata) has the shortest half-life of the z-drugs at approximately 1 hour, making it specifically useful for middle-of-the-night awakenings where the patient has at least 4 hours of sleep remaining. Like zolpidem and eszopiclone, zaleplon is Schedule IV.

Compared to both, doxepin 3 to 6 mg occupies a distinct niche: no scheduling, preservation of sleep architecture, no rebound insomnia, and specific evidence in older adults. Eszopiclone has a broader evidence base for sleep-onset plus sleep-maintenance insomnia combined; zaleplon is better suited to middle-of-night use than doxepin given its shorter half-life.

A simplified clinical matching framework:

| Patient presentation | Agent with Phase 3 support | |---|---| | Can't fall asleep, circadian phase delay | Melatonin / ramelteon | | Can't fall asleep, no circadian component | Zolpidem IR, eszopiclone, zaleplon | | Wakes early or mid-sleep, wants unscheduled drug | Doxepin 3 to 6 mg | | Wakes mid-night with 4+ hours remaining | Zaleplon (low half-life) | | Older adult, sleep maintenance, fall risk concern | Doxepin 3 mg (Beers-compatible; z-drugs flagged) | | Both onset and maintenance, long-term Rx acceptable | Eszopiclone (6-month trial data) |

Who Is an Appropriate Candidate for Doxepin at Sleep Doses?

Adults with chronic sleep-maintenance insomnia (difficulty staying asleep or waking too early, on at least 3 nights per week for at least 3 months) are the core population studied. The AASM defines chronic insomnia using exactly those parameters in its 2017 guideline. [7]

Doxepin is particularly worth considering in four overlapping groups:

1. Adults 65 and older. The 3 mg dose has explicit Phase 3 data in this population, [2] and older adults tolerate anticholinergic and GABA-modulating drugs poorly. A clinician prescribing zolpidem to a 72-year-old is prescribing against Beers Criteria guidance.

2. Patients with a history of substance use disorder. Because doxepin at sleep doses is unscheduled and has no recognized abuse potential, it does not raise the same clinical concerns that Schedule IV agents do for this population.

3. Patients who have failed or cannot tolerate z-drugs. Rebound insomnia after zolpidem discontinuation is a real barrier to stopping that medication; doxepin's clean discontinuation profile in Phase 3 data is a clinical advantage for patients trying to step down from chronic z-drug use.

4. Patients where next-day driving performance is a specific concern. The dedicated driving simulation study for doxepin 6 mg showed no significant next-morning impairment; zolpidem's FDA label was revised specifically because of documented next-morning blood levels above the impairment threshold.

Cognitive behavioral therapy for insomnia (CBT-I) remains the first-line treatment for chronic insomnia according to both the AASM 2017 guideline and the American College of Physicians Clinical Practice Guideline. [7][10] Pharmacotherapy, including doxepin, is appropriately used when CBT-I is unavailable, declined, or insufficient alone.

Practical Prescribing Considerations and Patient Counseling Points

A prescriber writing a doxepin prescription at the sleep dose should communicate several specific points to patients.

Take it within 30 minutes of bedtime, not earlier in the evening. Taking doxepin hours before bedtime can shift its sedative effect into the evening and increase fall risk in older adults.

Plan for a full 7 to 8 hours in bed. Doxepin's half-life at 3 to 6 mg is approximately 15 hours for the parent compound, though the active metabolite nordoxepin has a longer half-life. Patients who set an alarm 5 hours after taking the drug may feel sedated upon waking.

Avoid alcohol on doxepin nights. Alcohol is a CNS depressant and will compound sedation. The combination also raises the theoretical risk of respiratory depression in patients with underlying sleep-disordered breathing.

Do not take with a high-fat meal. A study comparing doxepin 6 mg taken with versus without food showed that a high-fat meal delayed T-max from roughly 3.5 hours to 5 hours and reduced C-max by approximately 15%. [3] This does not preclude a light snack but does mean patients should not take the pill immediately after a large dinner.

Report any new or worsening depression. Doxepin at antidepressant doses carries an FDA black-box warning for suicidality in patients under 25. At sleep doses the pharmacological rationale for this risk is much smaller, but the prescriber should review mood history at baseline and schedule a follow-up within 30 days of initiation.

The AASM recommends that pharmacotherapy for chronic insomnia be reassessed periodically, with a treatment goal of using the lowest effective dose for the shortest necessary duration. [7] In practice, some patients with chronic sleep-maintenance insomnia use doxepin 3 to 6 mg for extended periods without tolerance developing, which is consistent with the 35-night Phase 3 data showing sustained efficacy without dose escalation.